Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diosmin + hesperidin (Meprofarm)
- Development stage
- Phase 4
- Lead developer
- MEPROFARM
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Veridin is an oral phlebotonic and vasoprotective agent developed and marketed by Meprofarm. It is formulated as a film-coated tablet containing 500 mg of a micronized purified flavonoid fraction (MPFF) extracted from *Citrus sinensis* (sweet orange), consisting of 90% diosmin (450 mg) and 10% hesperidin (50 mg). Veridin is indicated for the symptomatic treatment of chronic venous insufficiency (CVI), varicose veins, and both acute and chronic hemorrhoidal disease. The active bioflavonoids work synergistically to improve venous tone by prolonging the vasoconstrictive activity of norepinephrine on the venous wall, reducing venous capacitance and stasis. Additionally, Veridin normalizes capillary permeability, increases capillary resistance to prevent microvascular leakage, and enhances lymphatic drainage to alleviate edema, pain, and heaviness in the lower limbs.
- Brand names
- Veridin
- Other names
- Citrus sinensis extractCitrus sinensis fructus extractdiosmin and hesperidindiosmin/hesperidinmicronized purified flavonoid fractionMPFF
02
Targets
AMPK (Adenosine monophosphate–activated protein kinase)AcetylcholinesteraseADRA1A (α1A)ADRA2A (α2A)ACE (Angiotensin Converting Enzyme)COMT (Catechol-O-methyltransferase)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)NOS2 (Nitric Oxide Synthase 2)NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)NF-κBPI3K (Phosphoinositide-3-kinase regulatory subunit 6)AKT (RAC-alpha serine/threonine-protein kinase)CACNA1B (Voltage-dependent N-type calcium channel subunit alpha-1B)
Beyond the preview
Go deeper on diosmin + hesperidin (Meprofarm).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diosmin + hesperidin (Meprofarm).